Xyclomed

Xyclomed

cyclophosphamide

Manufacturer:

Korea United Pharma

Distributor:

Qualimed
Concise Prescribing Info
Contents
Cyclophosphamide
Indications/Uses
Burkitt's & other Non-Hodgkin's lymphomas, multiple myeloma, leukemia, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, breast carcinoma, Wilm's tumour.
Dosage/Direction for Use
Induction: Patient w/o hematological deficiency 40-50 mg/kg IV in divided doses over a period of 2-5 days. Patient previously under radio- or chemotherapy which can decrease bone marrow function & patient whose bone marrow are tumor-infiltrated ½ to ⅓ of initial dose. Maintenance: 10-15 mg/kg/day every 7-10 days IV or 3-5 mg/kg/day twice a wk IV.
Contraindications
Patients under pentostatin therapy. Pregnancy & lactation.
Special Precautions
Leukopenia, thrombocytopenia, tumor cell infiltration of bone marrow, prior radio- or chemotherapy, impaired hepatic or renal function. Microbial, fungal or viral infections, herpes zoster, steroidal drugs. Monitor WBC.
Adverse Reactions
Cardiotoxicity, CHF; renal pelvic & urethral tumor; leukopenia, thrombocytopenia, anemia, acute leukemia, anorexia, nausea, vomiting, oral mucosa ulcer, jaundice, hemorrhagic colitis; hemorrhagic & non-hemorrhagic cystitis, hematuria, renal toxicity, ovarian fibrosis, alopecia, interstitial pulmonary fibrosis.
Drug Interactions
Rate of metabolism & leukopenic activity increase w/ phenobarb. Pentostatin.
ATC Classification
L01AA01 - cyclophosphamide ; Belongs to the class of alkylating agents, nitrogen mustard analogues. Used in the treatment of cancer.
Presentation/Packing
Form
Xyclomed powd for inj 1 g
Packing/Price
10 × 1's
Form
Xyclomed powd for inj 500 mg
Packing/Price
10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in